Phenotypic analysis by flow cytometry of surface immunoglobulin light chains and B and T cell antigens in lymph nodes involved with non-Hodgkin's lymphoma

Liendo, Cesar; Danieu, Linda; Al‐Katib, Ayad; Koziner, Benjamín

doi:10.1016/0002-9343(85)90031-2

Cited by 22 publications

(10 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As in the report of Glassman et al (12), a variety of benign lymph node histologies could not be categorized by FCI. In contrast to the report of Liendo et al (13), there were no cases in which there was a monoclonal B‐cell population by FCI and benign lymph node histology. There was 100% concordance between the cases negative by FCI and benign by histology (category A).…”

Section: Discussioncontrasting

confidence: 95%

Contribution of flow cytometric immunophenotyping to the evaluation of tissues with suspected lymphoma?

Dunphy

2000

Cytometry

View full text Add to dashboard Cite

Background: A critical analysis of the contribution of flow cytometric immunophenotyping (FCI) to the evaluation of lymph nodes and extranodal tissues with suspected lymphoma by a large, retrospective approach has not been reported previously and represents the purpose of this study. Methods: A total of 278 lymph nodes and 95 extranodal tissue specimens submitted over a 2‐year period with complete histologic, FCI, and immunohistochemical (IH) data formed the basis of the study. Results: The FCI data contributed significantly to or was consistent with the final tissue diagnosis in the majority (94%) of the tissue samples. There is no well‐described utility of flow cytometry markers for Hodgkin's lymphoma (HL) due to the usual scarcity of tumor cells in the final cell suspensions obtained from these tumors. However, the FCI data excluded non‐Hodgkin's lymphoma (NHL) and suggested the possible usefulness of CD15 and CD30 by FCI in HL. In addition, immunophenotypic data by FCI in combination with touch imprint cytomorphology was useful in excluding a diagnosis of NHL in cases of nonhematopoietic malignancies and was particularly useful in defining the following hematopoietic tumors and malignancies: thymoma, T‐cell lymphoblastic lymphoma, leukemia cutis, and plasma cell dyscrasia. Thus, IH was not essential for the diagnosis in these latter cases and was performed in only two cases (one thymoma and one plasma cell dyscrasia). Of interest, FCI supported the diagnosis in 3 cases of Ewing's sarcoma/primitive neuroectodermal tumor by detection of CD56 on the surface of the malignant cell. Only 11% of NHL were “negative” by FCI (i.e., an aberrant T‐cell or monoclonal B‐cell population was not identified). Reasons for these discrepancies included partial tissue involvement by the NHL with sampling differences, T‐cell rich or lymphohistiocytic‐rich variants with a small population of monoclonal B cells, marked tumoral sclerosis, poor tumor preservation, and T‐cell NHL without an aberrant immunophenotype. Only 60% of CD30+ anaplastic large cell lymphomas (ALCL) were CD30+ by FCI. Conclusions: FCI data should always be correlated with light microscopy if no FCI abnormalities are detected; IH may need to be performed in selected cases. It is less necessary to perform microscopic examination of tissues when the FCI data are positive and indisputable. However, in selected cases in which FCI data is diagnostic, microscopic observations may provide additional information due to sampling. Cytometry (Comm. Clin. Cytometry) 42:296–306, 2000. © 2000 Wiley‐Liss, Inc.

show abstract

Section: Discussioncontrasting

confidence: 95%

Contribution of flow cytometric immunophenotyping to the evaluation of tissues with suspected lymphoma?

Dunphy

2000

Cytometry

View full text Add to dashboard Cite

show abstract

“…Normally, either kappa or lambda light chains are expressed, and the great majority of B cell lymphomas show skewing of the normal kappa/lambda ratio or an otherwise obvious light chain-restricted population. [1][2][3][4][5][6][7][8] The absence of SIg light chain expression has been observed in about one third of B-cell non-Hodgkin lymphomas using immunohistochemical stain on frozen tissues; about 30% to 40% of these SIg-negative cases were diffuse large B-cell lymphoma and follicular lymphoma. 1 Subsequent studies using the relatively more sensitive FCI technique demonstrated that lack of SIg light chain expression in B-cell non-Hodgkin lymphoma was a rare phenomenon.…”

Section: Discussionmentioning

confidence: 99%

“…1 Subsequent studies using the relatively more sensitive FCI technique demonstrated that lack of SIg light chain expression in B-cell non-Hodgkin lymphoma was a rare phenomenon. [2][3][4][5][6][7][8] In the earliest study using FCI, Liendo et al 2 reported that 4 of 47 cases of B-cell non-Hodgkin lymphoma lacked SIg light chains, but the criteria for SIg negativity was not described. In a subsequent study by de Martini et al, 3 the absence of SIg was defined as B cells expressing less than 15% kappa and less than 10% lambda immunoglobulin light chains.…”

Section: Discussionmentioning

confidence: 99%

Lack of Surface Immunoglobulin Light Chain Expression by Flow Cytometric Immunophenotyping Can Help Diagnose Peripheral B-Cell Lymphoma

Eshleman

Borowitz

2002

Am J Clin Pathol

View full text Add to dashboard Cite

We determined the prevalence and significance of finding B cells without surface immunoglobulin (SIg) light chain expression. The flow cytometry database at Johns Hopkins Medical Institutions was searched for cases in which immunoglobulin light chain staining was performed to rule out a B-cell malignant neoplasm between January 1994 and February 2000. We excluded plasma cell dyscrasias, precursor B-cell acute lymphoblastic leukemia/lymphomas, and hematogones. Cases with more than 25% of B cells lacking SIg light chain expression were retrieved. Polymerase chain reaction assays for immunoglobulin heavy chain gene rearrangements were performed in SIg-negative cases with available tissue blocks. We identified 36 cases; all represented lymphoma. Their diagnoses included diffuse large B-cell lymphoma (20), HIV-related lymphoma (5), follicular lymphoma (5), Burkitt lymphoma (2), monomorphic posttransplant lymphoproliferative disorder (1), chronic lymphocytic leukemia/small lymphocytic lymphoma (1), marginal zone B-cell lymphoma (1), and low grade B-cell lymphoma (1). Of the 17 SIg-negative cases with amplifiable DNAs, 12 (71%) showed a clonal immunoglobulin heavy chain gene rearrangement. SIg-negative B-cell lymphomas are rare. Complete absence of SIg light chain expression in a mature B cell proliferation can be used as a surrogate marker to help diagnose peripheral B-cell lymphoma.

show abstract

“…Tumor cells were isolated with B cell negative isolation kit from Miltenyi Biotech, Inc., sorted out with anti-Lambda or anti-Kappa antibodies and labeled as tumor Ig light chain (C) B cells. 10,11 The normal B cells were sorted as the tumor Ig light chain (¡) B cells at same time. Monocytes were isolated with CD14 and MHC class II antibody.…”

Section: Normal Donors and Patient Samplesmentioning

confidence: 99%

Targeting B-cell malignancies through human B-cell receptor specific CD4⁺T cells

Weng¹,

Baio²,

Moriarty³

et al. 2016

OncoImmunology

View full text Add to dashboard Cite

The B-cell receptor (BCR) expressed by a clonal B cell tumor is a tumor specific antigen (idiotype). However, the T-cell epitopes within human BCRs which stimulate protective immunity still lack detailed characterization. In this study, we identified 17 BCR peptide-specific CD4 C T-cell epitopes derived from BCR heavy and light chain variable region sequences. Detailed analysis revealed these CD4 C T-cell epitopes stimulated normal donors' and patients' Th1 CD4C T cells to directly recognize the autologous tumors by secretion of IFNg, indicating the epitopes are processed and presented by tumor cells. One BCR peptide-specific CD4 C T cell line was also cytotoxic and lysed autologous tumor cells through the perforin pathway. Sequence analysis of the epitopes revealed that 10 were shared by multiple primary patients' tumors, and 16 had the capacity to bind to more than one HLA DRB1 allele. T cells stimulated by shared epitopes recognized primary tumors expressing the same sequences on multiple HLA DRB1 alleles. In conclusion, we identified 17 BCR-derived CD4C T-cell epitopes with promiscuous HLA DRB1 binding affinity that are shared by up to 36% of patients, suggesting a strategy to overcome the requirement for individual preparation of therapeutic agents targeting idiotype.

show abstract

Phenotypic analysis by flow cytometry of surface immunoglobulin light chains and B and T cell antigens in lymph nodes involved with non-Hodgkin's lymphoma

Cited by 22 publications

References 29 publications

Contribution of flow cytometric immunophenotyping to the evaluation of tissues with suspected lymphoma?

Contribution of flow cytometric immunophenotyping to the evaluation of tissues with suspected lymphoma?

Lack of Surface Immunoglobulin Light Chain Expression by Flow Cytometric Immunophenotyping Can Help Diagnose Peripheral B-Cell Lymphoma

Targeting B-cell malignancies through human B-cell receptor specific CD4⁺T cells

Contact Info

Product

Resources

About

Phenotypic analysis by flow cytometry of surface immunoglobulin light chains and B and T cell antigens in lymph nodes involved with non-Hodgkin's lymphoma

Cited by 22 publications

References 29 publications

Contribution of flow cytometric immunophenotyping to the evaluation of tissues with suspected lymphoma?

Contribution of flow cytometric immunophenotyping to the evaluation of tissues with suspected lymphoma?

Lack of Surface Immunoglobulin Light Chain Expression by Flow Cytometric Immunophenotyping Can Help Diagnose Peripheral B-Cell Lymphoma

Targeting B-cell malignancies through human B-cell receptor specific CD4+T cells

Contact Info

Product

Resources

About

Targeting B-cell malignancies through human B-cell receptor specific CD4⁺T cells